Protocol Ledger

NCT05144854 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including E

Interventional Phase III clinical trial protocol NCT05144854 sponsored by Ono Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-05 Enrollment: 626 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05144854
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)626 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05144854
Protocol FieldVerified Registry Value
NCT IdentifierNCT05144854
Consolidated Lead SponsorOno Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment626 participants (ACTUAL)
Registered Start Date2021-11-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05144854
Hospital Research SiteLocationSite Profile
Kanagawa Cancer CenterYokohama, JapanOpen Hospital Dossier ->
National Cancer Center HospitalChuo-ku, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI